Study to Evaluate Long-term Effectiveness and Safety, Patient Characteristics and Subjective Patient-reported Outcomes of Dupilumab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Under Real-world Conditions

Recruiting now

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

Study to evaluate the change of health-related quality of life, patient characteristics, efficacy and safety in Chronic Obstructive Pulmonary Disease (COPD) patients with Dupilumab therapy in a real-world setting over 24 months.

Key facts

Study ID

NCT07052396

Run by

Sanofi

People needed

350

Starts

2025-07-01

Expected to finish

2029-07-01

Last updated by the study team

2025-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants willing and able to sign informed consent for use of their pseudonymized clinical data within the present non-intervention study.
• Adult participants.
• Participants with uncontrolled Chronic Obstructive Pulmonary Disease (COPD) despite long-acting muscarinic antagonist (LAMA)/ long-acting beta2-agonist (LABA)/ Inhaled Corticosteroid (ICS) (or LAMA/LABA if ICS are not appropriate) therapy and elevated blood eosinophils
• Participants newly initiated on dupilumab treatment as indicated in the dupilumab Summary of Product Characteristics (SmPC) in the specified label for COPD, determined by the treating physician, and independent of participation in the non-interventional study (NIS).

You may not qualify if…

• Participants not eligible for dupilumab treatment according to SmPC.
• Participation in an ongoing interventional or observational study or participation in an interventional or observational study up to 12 months before enrolment that might, in the treating physician's opinion, influence the assessments for the current study.
• Any acute or chronic condition that, in the treating physician´s opinion, would limit the participants´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results.
• Participants hospitalized due to an exacerbation of their COPD within the last 4 weeks prior to enrolment.

Where it is running

• Investigational Site Number: DE18 — Auerbach, Germany (enrolling)
• Investigational Site Number: DE21 — Augsburg, Germany (enrolling)
• Investigational Site Number: DE13 — Bad Homburg, Germany (enrolling)
• Investigational Site Number: DE19 — Berlin, Germany (enrolling)
• Investigational Site Number: DE02 — Berlin, Germany (enrolling)
• Investigational Site Number: DE29 — Burgwedel, Germany (enrolling)
• Investigational Site Number: DE01 — Darmstadt, Germany (enrolling)
• Investigational Site Number: DE09 — Erkelenz, Germany (enrolling)
• Investigational Site Number: DE06 — Flensburg, Germany (enrolling)
• Investigational Site Number: DE08 — Fürstenwalde, Germany (enrolling)
• Investigational Site Number: DE03 — Hamburg, Germany (enrolling)
• Investigational Site Number: DE04 — Hamburg, Germany (enrolling)
• Investigational Site Number: DE07 — Hohenstein-Ernstthal, Germany (enrolling)
• Investigational Site Number: DE10 — Itzehoe, Germany (enrolling)
• Investigational Site Number: DE24 — Kaiserslauten, Germany (enrolling)
• Investigational Site Number: DE25 — Lüneburg, Germany (enrolling)
• Investigational Site Number: DE20 — Marburg, Germany (enrolling)
• Investigational Site Number: DE14 — Markkleeberg, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.